Research scenario Better conceptual fit Reason Testing GLP-1 plus satiety-pathway extension CagriSema Combines semaglutide with amylin analog activity Testing maximum receptor breadth Retatrutide Activates GIP, GLP-1, and glucagon receptors Studying diabetes plus obesity together Both Both have programs relevant to T2D and weight Comparing incremental vs radical next-gen strategy Both CagriSema extends GLP-1
doi:10.1126/scitranslmed.add1531 [52] Hulme H, Meikle LM, Strittmatter N, et al
Indeed, a critical barrier that the obesity research field must overcome is to find pharmacotherapies that can break-through the plateau of weight loss that occurs with every existing FDA-approved treatment for obesity 1,24,25,26,27,28
First, we lack large-scale, long-term studies proving its beneficial effects on humans
But if youve been running on empty, itll take time to replenish your levels before you start feeling real benefits
Document every use